<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30344713</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1792-1074</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>16</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Oncology letters</Title>                <ISOAbbreviation>Oncol Lett</ISOAbbreviation>            </Journal>            <ArticleTitle>Elevated expression of POLD1 is associated with poor prognosis in breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>5591-5598</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2018.9392</ELocationID>            <Abstract>                <AbstractText>Polymerase δ catalytic subunit gene 1 (POLD1) may serve an important function in the development of tumors. However, its role in breast cancer remains unclear. The aim of the present study was to observe the expression and the function of POLD1 in breast cancer. A total of 84 patients with invasive breast carcinoma were recruited between 2011 and 2013. The expression of POLD1 was detected in paired tumor and adjacent normal tissues. Gene expression level of POLD1 was assessed using reverse transcription quantitative polymerase chain reaction. The protein expression of POLD1 was assessed using western blot analysis. The association between the clinicopathological features of patients with breast cancer and POLD1 expression was analyzed using a χ<sup>2</sup> test. Disease-free survival (DFS) was analyzed using Kaplan-Meier method, and Cox regression analysis was performed to investigate clinicopathological significance of POLD1 expression. Additionally, the effects of POLD1 in regulating cell cycle and proliferation of MCF-7 cells were evaluated <i>in vitro</i>. The results demonstrated that gene and protein expression levels of POLD1 were significantly elevated in breast cancer tissues compared with those in adjacent normal tissues. Increased expression of POLD1 was significantly associated with positive lymph node status (P=0.028), histological grade (P=0.025), p53 status (P&lt;0.001) and ki-67 index (P=0.020). Survival analysis demonstrated that increased expression of POLD1 was associated with poor DFS (P=0.033). Additionally, increased expression of POLD1 was associated with shorter DFS at early-stage (P=0.037), late-stage cases (P=0.023) and with the presence of triple-negative tumors (TNBC; P=0.049). Multivariate analysis revealed that POLD1 may be used as an independent prognostic factor in patients with breast cancer. <i>In vitro</i> studies revealed that downregulation of POLD1 suppressed cell cycle progression and proliferation in MCF-7 cells. In conclusion, POLD1 may be considered as a potential prognostic marker for invasive breast carcinoma.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Qin</LastName>                    <ForeName>Qinghong</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tan</LastName>                    <ForeName>Qixing</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Jinyuan</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Weiping</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Ultrasound Diagnosis, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lian</LastName>                    <ForeName>Bin</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mo</LastName>                    <ForeName>Qinguo</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wei</LastName>                    <ForeName>Changyuan</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Oncol Lett</MedlineTA>            <NlmUniqueID>101531236</NlmUniqueID>            <ISSNLinking>1792-1074</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Chromosomes Cancer. 2007 Apr;46(4):373-84</RefSource>                <PMID Version="1">17243165</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncology. 2010;79(3-4):229-37</RefSource>                <PMID Version="1">21372597</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2001 Aug 10;276(32):29729-39</RefSource>                <PMID Version="1">11375983</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2000 Jun 23;275(25):18739-44</RefSource>                <PMID Version="1">10751307</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2010 Jun 15;116(12):2856-67</RefSource>                <PMID Version="1">20564392</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Methods. 2001 Dec;25(4):402-8</RefSource>                <PMID Version="1">11846609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15560-5</RefSource>                <PMID Version="1">12429860</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Pathol. 2012 Feb;180(2):457-72</RefSource>                <PMID Version="1">22142811</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Genet. 2013 Feb;45(2):136-44</RefSource>                <PMID Version="1">23263490</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Aug;22(8):1736-47</RefSource>                <PMID Version="1">21709140</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Onco Targets Ther. 2016 Mar 10;9:1351-60</RefSource>                <PMID Version="1">27022290</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gene. 2016 Sep 15;590(1):128-41</RefSource>                <PMID Version="1">27320729</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2016 Apr;141(1):113-20</RefSource>                <PMID Version="1">26748215</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Mar;65(2):87-108</RefSource>                <PMID Version="1">25651787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Ther Med. 2013 Oct;6(4):1070-1076</RefSource>                <PMID Version="1">24137319</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2012;7(8):e40521</RefSource>                <PMID Version="1">22905093</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Biochem. 2015 Jun 19;16:14</RefSource>                <PMID Version="1">26087769</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29</RefSource>                <PMID Version="1">25559415</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Biol. 2007 Nov;27(21):7669-82</RefSource>                <PMID Version="1">17785453</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Mutat. 2015 Nov;36(11):1070-9</RefSource>                <PMID Version="1">26172944</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2004 Mar 12;4:9</RefSource>                <PMID Version="1">15113441</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2018 Jan;62:110-122</RefSource>                <PMID Version="1">29202431</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2015 Feb;116(2):299-309</RefSource>                <PMID Version="1">25187488</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">biomarker</Keyword>            <Keyword MajorTopicYN="N">breast carcinoma</Keyword>            <Keyword MajorTopicYN="N">polymerase δ catalytic subunit gene 1</Keyword>            <Keyword MajorTopicYN="N">prognosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>04</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30344713</ArticleId>            <ArticleId IdType="doi">10.3892/ol.2018.9392</ArticleId>            <ArticleId IdType="pii">OL-0-0-9392</ArticleId>            <ArticleId IdType="pmc">PMC6176253</ArticleId>        </ArticleIdList>        <?pmcsd?>    </PubmedData></PubmedArticle></PubmedArticleSet>